AZD-3965
- Generic Name
- AZD-3965
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Adult Solid TumorDiffuse Large B Cell LymphomaBurkitt Lymphoma
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 53
- Registration Number
- NCT01791595
- Locations
- 🇬🇧
The Beatson West of Scotland, Glasgow, Glasgow, United Kingdom
🇬🇧Royal Marsden Hospital, Sutton, London, United Kingdom
🇬🇧Leicester Royal Infirmary, Leicester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath